Serial No.: 10/549,868

Filed: September 21, 2005

Page : 2 of 8

Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in the application:

1. (Original) A compound of formula (I):

$$R^{1} \xrightarrow{W} Q \qquad X \xrightarrow{Z^{3}} Y \qquad (I)$$

wherein:

E is CH or N;

Q is hydrogen or hydroxy;

W is CH_2 , O or NR^2 ;

X is a bond, CH₂ or CH₂O;

Y is OH, CO₂R³, SO₃H, CH₂CO₂R³, CH₂SO₃H, OCH₂CO₂R³ or OCH₂SO₃H;

 Z^1 , Z^2 , Z^3 are, independently, hydrogen, halogen, cyano, nitro, hydroxy, NR^4R^5 , C_{1-6} alkyl (optionally substituted with halogen), C_{1-6} alkoxy (optionally substituted with halogen), $S(O)_p(C_{1-6}$ alkyl), $S(O)_qCF_3$ or $S(O)_2NR^6R^7$;

 R^1 is phenyl optionally substituted by halogen, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy or C_{1-4} haloalkoxy;

R² is hydrogen or C₁₋₄ alkyl;

R³ is hydrogen, C₁₋₆ alkyl or benzyl;

p and q are, independently, 0, 1 or 2;

 R^4 , R^5 , R^6 and R^7 are, independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl), $CH_2(C_{2-5}$ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^4 and R^5 below), $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to

Serial No.: 10/549,868

Filed: September 21, 2005

Page : 3 of 8

form a ring as described for R⁴ and R⁵ below), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁴ and R⁵ below), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁴ and R⁵ below), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁴ and R⁵ below), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁴ and R⁵ below), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃); alternatively NR⁴R⁵ or NR⁶R⁷ may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, the latter optionally substituted by C₁₋₄ alkyl on the distal nitrogen; or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

- 2. (Original) A compound of formula (I) as claimed in claim 1 wherein W is O.
- 3. (Previously presented) A compound of formula (I) as claimed in claim 1 wherein E is CH.
- 4. (Previously presented) A compound of formula (I) as claimed in claim 1 wherein R^1 is phenyl optionally substituted with halogen, C_{1-4} alkyl or C_{1-4} alkoxy.
- 5. (Previously presented) A compound of formula (I) as claimed in claim 1 wherein Y is CO₂H, CO₂(C₁₋₄ alkyl), CH₂CO₂H or OH.
- 6. (Previously presented) A compound of formula (I) as claimed in claim 1, wherein Z¹, Z² and Z³ are, independently, hydrogen, halogen, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, S(O)₂(C₁₋₄ alkyl) or S(O)₂NH₂.

Serial No.: 10/549,868

Filed: September 21, 2005

Page : 4 of 8

7. (Withdrawn) A process for preparing a compound of formula (I) as claimed in claim 1, the process comprising:

a. when Y is CO₂H, CH₂CO₂H or OCH₂CO₂H, said Y group being ortho to the group X, acylating a compound of formula (II):

$$R^{1}$$
 N NH (II)

via the ring opening of an anhydride of formula (III):

$$Z^{2} \xrightarrow{A_{||}^{2}} A^{1} \xrightarrow{X} O$$

$$Z^{2} \xrightarrow{A_{||}^{3}} A^{4} \xrightarrow{Y^{1}} O$$
(III)

wherein one of A^1 , A^2 , A^3 and A^4 is CH or N; the other three of A^1 , A^2 , A^3 and A^4 are carbon and each of the three carries Z^1 , Z^2 or Z^3 , there being only one of each of Z^1 , Z^2 and Z^3 ; X is as defined in claim 1; and Y^1 is a bond, CH_2 or OCH_2 ; in the presence of a suitable tertiary amine, in a suitable solvent at an elevated temperature;

b. when Y is CO₂R³, CH₂CO₂R³ or OCH₂CO₂R³ and R³ is not hydrogen, coupling a compound of formula (II) with a compound of formula (IV):

HO
$$X \xrightarrow{Z^3} Y$$
 $Z^2 \text{ (IV)}$

either going via the acid chloride of the compound of formula (IV) or by using a coupling reagent;

c. when X is a bond and Y is CO_2R^3 , carbonylating a compound of formula (V):

Serial No.: 10/549,868

Filed: September 21, 2005

Page : 5 of 8

$$Z^3$$
 Y Z^2 (V)

wherein L is chloro, bromo, iodo or O-triflate, and then quenching the product so formed with a compound of formula (II);

- d. when X is a bond, Y is CO₂R³, R³ is not hydrogen, and R¹ does not have a chloro, bromo or iodo substituent,
 - i. coupling a compound of formula (II) with an acid of formula (VI):

wherein Hal is chloro, bromo or iodo;

- ii. carbonylating the compound so formed; and then,
- iii. quenching the product so formed with a C_{1-6} aliphatic alcohol or benzylalcohol;

OR

- e. when Y is or includes a CO₂R³ group:
 - i. when R³ is hydrogen said compound can be converted to a compound of the invention where R³ is not hydrogen by a standard esterification method; or
 - ii. when R³ is not hydrogen said compound can be converted to a compound of the invention where R³ is hydrogen by a standard ester hydrolysis method.
- 8. (Withdrawn) A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.

Serial No.: 10/549,868

Filed: September 21, 2005

Page : 6 of 8

9-10. (Cancelled)

- 11. (Withdrawn) A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.
- 12. (Previously presented) A compound of formula (I) as claimed in claim 2, wherein E is CH.
- 13. (Previously presented) A compound of formula (I) as claimed in claim 2, wherein R^1 is phenyl optionally substituted with halogen, C_{1-4} alkyl or C_{1-4} alkoxy.
- 14. (Previously presented) A compound of formula (I) as claimed in claim 3 wherein R^1 is phenyl optionally substituted with halogen, C_{1-4} alkyl or C_{1-4} alkoxy.
- 15. (Previously presented) A compound of formula (I) as claimed in claim 2, wherein Y is CO_2H , $CO_2(C_{1-4}$ alkyl), CH_2CO_2H or OH.
- 16. (Previously presented) A compound of formula (I) as claimed in claim 3, wherein Y is CO_2H , $CO_2(C_{1-4}$ alkyl), CH_2CO_2H or OH.
- 17. (Previously presented) A compound of formula (I) as claimed in claim 4, wherein Y is CO₂H, CO₂(C₁₋₄ alkyl), CH₂CO₂H or OH.
- 18. (Previously presented) A compound of formula (I) as claimed in claim 2, wherein Z¹, Z² and Z³ are, independently, hydrogen, halogen, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, S(O)₂(C₁₋₄ alkyl) or S(O)₂NH₂.

Serial No.: 10/549,868

Filed: September 21, 2005

Page : 7 of 8

19. (Previously presented) A compound of formula (I) as claimed in claim 3, wherein Z^1 , Z^2 and Z^3 are, independently, hydrogen, halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3 , CF_3 , $S(O)_2(C_{1-4}$ alkyl) or $S(O)_2NH_2$.

- 20. (Previously presented) A compound of formula (I) as claimed in claim 4, wherein Z^1 , Z^2 and Z^3 are, independently, hydrogen, halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3 , CF_3 , $S(O)_2(C_{1-4}$ alkyl) or $S(O)_2NH_2$.
- 21. (Previously presented) A compound of formula (I) as claimed in claim 5, wherein Z^1 , Z^2 and Z^3 are, independently, hydrogen, halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3 , CF_3 , $S(O)_2(C_{1-4}$ alkyl) or $S(O)_2NH_2$.